Drugs / INCB123667
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT07559396 | May 2026 → Jan 2027 expected | impaired renal function disease | Incyte Corporation | Recruiting | No outcome recorded |
| Phase 1 | NCT07559474 | May 2026 → Apr 2027 expected | liver disorder | Incyte Corporation | Recruiting | No outcome recorded |
| Phase 1 | NCT07218744 | Nov → Dec 2025 | — | Incyte Corporation | Completed | No outcome recorded |
| Phase 1 | NCT06909162 | May 2025 → May 2026 | — | Incyte Corporation | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07023627 | Nov 2025 → Apr 2027 expected | ovarian cancer | Incyte Corporation | Recruiting | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07797283 | Dec 2026 → May 2032 expected | ovarian cancer | Incyte Corporation | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07214779 | Dec 2025 → Nov 2028 expected | ovarian cancer | Incyte Corporation | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2024-09-14 | Incyte Corporation | Results Incyte’s CDK2 Inhibitor INCB123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer incyte.com ↗
Incyte (Nasdaq:INCY) today announced new early clinical data for INCB123667, a highly selective, potential first-in-class CDK2 inhibitor, in patients with advanced solid tumors. |
| 2024-01-08 | Incyte Corporation | Results Incyte Highlights Growth Opportunities and Provides Business Updates at the 42nd Annual J.P. Morgan Healthcare Conference incyte.com ↗
In a Phase 1 study of INCB123667, early clinical activity was observed with several patients with amplified/overexpression of CCNE1, a cell cycle regulator and potential predictive biomarker, achieving partial response (PR). |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-09-14 | Incyte Corporation | Incyte’s CDK2 Inhibitor INCB123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer incyte.com ↗ |
| 2024-01-08 | Incyte Corporation | Incyte Highlights Growth Opportunities and Provides Business Updates at the 42nd Annual J.P. Morgan Healthcare Conference incyte.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INCB123667 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07559474 ↗ |
| Route | Oral | “single dose administered orally” NCT06909162 ↗ |